BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 202
Go back to BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 202| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 55.49 +0.80 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.69 | 52 Week High | $108.96 | |||
| Open | $55.51 | 52 Week Low | $62.12 | |||
| Day High | $55.87 | P/E | N/A | |||
| Day Low | $54.96 | EPS | $-1.27 | |||
| Volume | 849,698 | |||||
